• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

USTEKINUMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • USTEKINUMAB chembl:CHEMBL1201835 ApprovedImmunotherapy

    Alternate Names:

    STELERA
    STELARA
    USTEKINUMAB
    CNTO-1275
    USTEKINUMAB
    TT-20
    drugbank:05679
    chemidplus:815610-63-0
    chembl:CHEMBL1201835
    rxcui:847083

    Drug Info:

    FDA Approval 2009
    Drug Class monoclonal antibody
    Drug Indications Antipsoriatic Agents
    Year of Approval 2009
    Drug Class antipsoriatic agents
    (3 More Sources)

    Publications:

    van den Reek JMPA et al., 2017, Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis., Br J Dermatol
    Talamonti M et al., 2013, Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab., Br J Dermatol
    Khanna et al., 2016, The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews., Inflamm. Bowel Dis.
    Engel et al., 2016, Ustekinumab in Crohn's disease: evidence to date and place in therapy., Ther Adv Chronic Dis
    Wittig, 2007, Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases., Curr Opin Investig Drugs
    Reddy et al., 2007, Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275., Cell. Immunol.
    Loft ND et al., 2018, Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis., Pharmacogenomics J
    Prieto-Pérez R et al., 2017, Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis., Pharmacogenomics
  • USTEKINUMAB   TIRAP

    Interaction Score: 12.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28696418


    Sources:
    PharmGKB

  • USTEKINUMAB   IL12B

    Interaction Score: 12.37

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Interleukin-12 inhibitor
    Direct Interaction yes
    Trial Name -

    PMIDs:
    27306074 27433311 27564082 17979029 17761156


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB FDA

  • USTEKINUMAB   TNFAIP3

    Interaction Score: 9.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27564082 23521149


    Sources:
    PharmGKB

  • USTEKINUMAB   AGBL4

    Interaction Score: 6.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27977334


    Sources:
    PharmGKB

  • USTEKINUMAB   TLR5

    Interaction Score: 6.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28696418


    Sources:
    PharmGKB

  • USTEKINUMAB   IL12A

    Interaction Score: 6.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Interleukin-12 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions PharmGKB TTD FDA

  • USTEKINUMAB   IL23A

    Interaction Score: 6.18

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name -
    Mechanism of Interaction Interleukin-23 inhibitor

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD FDA

  • USTEKINUMAB   HLA-C

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23521149


    Sources:
    PharmGKB

  • USTEKINUMAB   PDF

    Interaction Score: 0.88

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • USTEKINUMAB   IL1B

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28696418


    Sources:
    PharmGKB

  • TEND: USTEKINUMAB

    • Version: 01-August-2011

    Alternate Names:
    USTEKINUMAB Primary Drug Name

    Drug Info:
    Drug Class antipsoriatic agents
    Year of Approval 2009

    Publications:

  • TdgClinicalTrial: USTEKINUMAB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications Antipsoriatic Agents
    Drug Class monoclonal antibody
    FDA Approval 2009

    Publications:

  • PharmGKB: ustekinumab

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    van den Reek JMPA et al., 2017, Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis., Br J Dermatol
    Talamonti M et al., 2013, Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab., Br J Dermatol
    Loft ND et al., 2018, Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis., Pharmacogenomics J

  • TTD: Ustekinumab

    • Version: 2020.06.01

    Alternate Names:
    D0A2UV TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1201835

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1201835

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Ustekinumab

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21